Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 21, 1989 - Issue sup68
Submit an article Journal homepage
41
Views
0
CrossRef citations to date
0
Altmetric
Miscellany

New Perspectives on Ofloxacin: Proceedings of a Symposium Held in West Berlin, 16 October 1989

S. Ragnar Norrby
Pages 1-69 | Published online: 02 Jan 2015

References

  • Midtvedt T. Anti-infectives for systemic use. In: Sakshaug S, Andrew M, Hjort PF, Lunde PKM, Øydvin K, eds. Drug utilization in Norway during the 1970s—increases, inequalities, innovations. Oslo: Aktietrykkeriet, 145–161, 1983
  • Nordic Statistics on Medicines. NLN Publication No. 21. Nordic Council of Medicines, Uppsala, Sweden, 1988
  • Öydvin K. Legemiddelforbruket i Norge 1984–1988. Norsk Medisinaldepot, Oslo, Norge, 1988
  • Ringertz S, Björklind A, Kronvall G. Species-specific interpretative breakpoints for ciprofloxacin disc diffusion susceptibility testing. Scand J Infect Dis, Suppl. 60: 46–53, 1989
  • Midtvedt T, Hansen E. Urinisolater fra sykehuspasienter: Forekomst og antibiotikafølsomhet. In: Urinveisinfeksjoner Symposium, Solstrand, Astra Farmasøytiske A/S, 115–117, 1982
  • Hovig B, Sykehuspatogener, presentasjon av et databehandlet materiale. In: Norsk Gentamicin Symposium, Oslo: Schering Corporation, 64–72, 1978
  • Hovig B. Bakterier isolert fra urinprøver fra eldre. Arter og antibiotikafølsomhet i et sykehusmateriale. In: Digranes A, ed. Urinveisinfeksjoner hos eldre. Oslo: Nyegaard & Co., 59–69, 1982
  • Hovig B, Melby K. Species distribution and antibiotic sensitivity pattern of urinary tract bacteria in hospitalised patients in Norway. NIPH Ann 4: 1–9, 1981
  • Digranes A, Bernhardsen S. Urinveispatogene bakterier fra sykehus og almenpraksis. Frekvens og resistensforhold. Tidsskr Nor Laegeforen 98: 156–158, 1978
  • Digranes A. Bakterier isolert fra sykehuspasienter: Arter og antibiotikafølsomhet. In: Norsk Gentamicin Symposium. Oslo: Schering Corporation, 57–63, 1978
  • Digranes A. Bakterier isolert fra urinprøver fra eldre. Arter og antibiotikafølsomhet i et materiale fra Haukeland sykehus 1975–1979. In: Digranes A, ed. Urinveisinfeksjoner hos eldre. Oslo: Nyegaard & Co., 71–77, 1982
  • Kayser FH, Muzinger JWJ. Empfindlichkeit von Bakterien gegenüber Chemotherapeutika (Zurich, 1980). Teil 1. Von Spitalpatienten isolierte Bakterien. Schweiz Med Wochenschr 112: 411–414, 1982
  • Burman LG, Holm SE: Antibiotikaresistens vid urinvägsinfektion i Sverige 1976. Läkartidningen 75: 781–783, 1978. (Swedish).
  • Størvold G, Gossius G, Vorland L. Urinveispatogene bakterier—Et materiale fra almenpraksis i Nord-Norge 1983–84. In: Trimetroprim ved urinveisinfeksjoner Symposium. NAF Laboratoriene A/S, 43–47, 1984
  • Dibb WL, Digranes A. Antibiotikafølsomhet hos urinveispatogene bakterier. Et materiale fra almenpraksis 1983. In: Trimetoprim ved urinveisinfeksjoner Symposium. NAF Laboratoriene A/S, 39–42, 1984
  • Digranes A. Antibiotikafølsomhet hos urinisolater fra almenpraksis. In: Urinveisinfeksjoner Symposium, Solstrand, Astra Farmasøytiske A/S, 111–114, 1982
  • Thamsborg GM, Balslev I, Mabeck CE, Vejlsgaard R. Urinveisinfeksjoner i almen praksis. I. Klinisk billede og bakterieflora. Ugeskr Laeger 142: 1657–1659, 1980
  • Ferry S, Burman LG. Urinary tract infection in primary health care i Northern Sweden. Scand J Prim Health Care 5: 233–240, 1987
  • Hooper D. Quinolones and membranes. Lecture given in Session 67 at the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, USA, 1989
  • Munshi MH, Sack DA; Haider K, Ahmed ZU, Rahaman MM, Morshed MG. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet 2: 419–421, 1987
  • Rimland D, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA). 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, USA, September 1989, Abstract 7, 1989.
  • Jones RN, Bouchillon S. Lomefloxacin international surveillance trial: Interim report. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, USA, 1989, Abstract 93, 1989.
  • Neu HC. Quinolones—new developments. VIth Mediterranean Congress of Chemotherapy, Taormina, Italy, 1988

References

  • Midtvedt T. Influence of antibiotics on biochemical intestinal microflora-associated characteristics in man and animals. In: Gillissen G, Opferkuch W, Peters G, Pulverer G, eds. The influence of antibiotics on the host–parasite relationship III. Heidelberg, Berlin: Springer-Verlag, 209–215, 1989
  • Bergan T, Delin C, Johansen S, Kolstad IM, Nord CE, Thorsteinsson SB. Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob Agents Chemother 29: 298–302, 1987
  • Brumfitt W, Franklin I, Grady D, Hamilton-Miller JMT, Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother 26: 757–761, 1984
  • Enzenberger R, Shah PM, Knothe H. Impact of oral ciprofloxacin on the faecal flora of healthy volunteers. Infection 13: 273–275, 1985
  • Rozenberg-Arska M, Dekker AW, Verhoef J. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: The effect on faecal flora. J Infect Dis 152: 104–107, 1985
  • Esposito S, Barba D, Galante D, Gaeta GB, Laghezza O. Changes in intestinal microflora induced by ciprofloxacin and treatment of portal-systemic encephalopathy (extended abstract). Rev Infect Dis 10, Suppl 1: 197, 1988
  • Rademaker CMA, Hoepelman IM, Wolfhagen Mjhm, Vos NM, Rozenberg-Arska M, Verhoef J. Changes in faecal flora during travel: Effective prophylaxis with ciprofloxacin (CF) in travellers' diarrhea. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, USA, September 1989, Abstract No. 22, 1989.
  • Van Saene JJM, van Saene HKF, Geitz JN, Lerk CF. Effects of ciprofloxacin on the intestinal flora (extended abstract). Rev Infect Dis 10, Suppl 1: 198, 1988
  • Nord CE, Brismar B, Edlund C. Effect of lomefloxacin on the normal oropharyngeal and intestinal microflora. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, USA, Abstract No. 1278, 1989
  • Edlund C, Bergan T, Josefsson K, Solberg R, Nord CE. Effect of norfloxacin on human oropharyngeal and colonic microflora and multiple-dose pharmacokinetics. Scand J Infect Dis 19: 113–121, 1987
  • Meckenstock R, Haralambie E, Linzenmeier G, Wendt F. Die Beeinflussung der Darmflora durch Norfloxacin bei gesunden Menschen. Z Antimikrob Antineoplast Chemother 1: 27–34, 1985
  • Van Saene HKF, Boerema JBJ. The evaluation of norfloxacin as decontaminating agent in patients with complicated urinary tract infections. International Symposium on the New Quinolones, Geneva, 207, 1986
  • Pecquet S, Andremont A, Tancrede C. Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human faecal flora. Antimicrob Agents Chemother 29: 1047–1052, 1986
  • Chida T, Shibaoka H, Ishizuka I, Nakaya R. The effect of ofloxacin (DL 8280), a new antibacterial agent of pyridone-carboxylic acid derivative, on human faecal flora. Chemotherapy 30: 109–117, 1984
  • Van Saene JJM, van Saene HKF, Tarko-Smit NJP, Lerk CF. Suppression of intestinal flora by perfloxacin in human volunteers. International Symposium on the New Quinolones. Geneva, 205, 1986
  • Midtvedt T. Influence of ofloxacin on the faecal flora. Drugs 34 ( Suppl 1): 154–158, 1987
  • Midtvedt T, Bjørneklett A, Carlstedt-Duke B, Gustafsson BE, Høverstad T, Lingaas E, Norin KE, Saxerholt H, Steinbakk M. The influence of antibiotics upon microflora-associated characteristics in man and mammals. In: Wostmann BS, ed. Germfree research—Microflora control and its application to the biomedical sciences. New York: Alan R Liss Inc., 241–244, 1985
  • Midtvedt T, Carlstedt-Duke B, Høverstad T, Lingaas E, Norin E, Saxerholt H, Steinbakk M. Influence of peroral antibiotics upon the biotransformatory activity of the intestinal microflora in healthy subjects. Eur J Clin Invest 16: 11–17, 1986
  • Grubb R, Midtvedt T, Norin E, eds. The regulatory and protective role of the normal microflora. Wenner-Gren International Symposium Series. Houndmills, Basingstoke, Hampshire, London: Macmillan Press, 52: 1–416, 1989
  • Midtvedt T. The normal microflora, intestinal motility and influence of antibiotics. An overview. In: Grubb R, Midtvedt T, Norin E, eds. The regulatory and protective role of the normal microflora. Wenner-Gren International Symposium Series. Volume 52. Houndmills, Basingstoke, Hampshire, London: Macmillan Press, 147–167, 1989

References

  • Paton JH, Reeves DS. Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use. Drugs 36: 193–228, 1988
  • Report from a Swedish study group. Randomised double-blind comparison of norfloxacin and cefadroxil for treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis. In press.
  • Bergan T. Pharmacokinetics of fluorinated quinolones. In: Andriole VT, ed. The quinolones. Bayer: Academic Press, 119–154, 1988
  • Bergan T. Pharmacokinetic properties of the cephalosporins. Drugs 34, Suppl 2: 89–104, 1987
  • Haykawa I, Atarashi S, Yokohama S, Imamura M, Sakano K-I, Furukawa M. Synthesis and antibacterial activities of optically active ofloxacin. Antimikrob Agents Chemother 29: 163–164, 1986
  • Wise R, Lockley MR. The pharmacokinetics of ofloxacin and a review of its tissue penetration. J Antimicrob Chemother 22, Suppl C: 59–64, 1988
  • Monk JP, Campoli-Richards DM. Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 33: 346–391, 1987
  • Holmes B, Brogden RN, Richards DM. Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 30: 482–513, 1985
  • Campoli-Richards DM, Monk JP, Price A, Benfield P, Todd PA, Ward A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 35: 373–447, 1988
  • Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of ciprofloxacin in the elderly: Increased oral bioavailability and reduced renal clearance. Eur J Clin Microbiol Infect Dis 8: 515–520, 1989
  • Edlund C, Nord C-E. Suppression of the oropharyngeal and gastrointestinal microflora by ciprofloxacin: Microbiological and clinical consequences. Scand J Infect Dis, Suppl. 60: 98–103, 1989
  • Bergan T, Thorsteinsson SB, Rohwedder R, Scholl H. Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function. Chemotherapy, in press.
  • Rohwedder R, Bergan T, Thorsteinsson SB, Scholl H. Transintestinal elimination of ciprofloxacin. Chemotherapy, in press.
  • Schach von Wittenau M, Twomey TM. The disposition of doxycycline by man and dog. Chemotherapy 16: 217, 1971

References

  • Kuo C-C, Chen HH, Wang SP, Grayston JT. Identification of a new group of Chlamydia psittaci strains called TWAR. J Clin Microbiol 24: 1034–1037, 1986
  • Wang SP, Grayston JT, Alexander ER, Holmes KK. Simplified microimmunofluorescence test with trachoma lymphogranuloma venereum (Chlamydia trachomatis) antigens for use as a screening test for antibody. J Clin Microbiol 1: 250–255, 1975
  • Mårdh P-A, Paavonen J, Puolakkainen M. Chlamydia. New York: Plenum Press, 263–275, 1989
  • Mårdh P-A, Helin I, Bobeck S. Colonization of pregnant and puerperal women and neonates with Chlamydia trachomatis. Br J Vener Dis 56: 96–100, 1980
  • Grayston JT, Wang SP; Kuo CC, Campbell LA. Current knowledge on Chlamydia pneumoniae, strain TWAR, an important cause of pneumonia and other acute respiratory diseases. Eur J Clin Microbiol Infect Dis 8: 191–202, 1989
  • Mordhorst CH, Wang SP, Grayston JTT. Epidemic “ornithosis” and TWAR infections, Denmark 1976–1985. In: Oriel J, Ridgway G, Schachter J, Taylor-Robinson D, Ward M, eds. Chlamydial infections. Cambridge: Cambridge University Press, 326–328, 1986
  • Schachter J. Human Chlamydia psittaci infection. In: Oriel J, Ridgway G, Schachter J, Taylor-Robinson D, Ward M, eds. Chlamydial infections. Cambridge: Cambridge University Press, 311–320, 1986
  • Mårdh P-A, Paavonen J, Puolakkainen M. Chlamydia. New York: Plenum Press, 264–265, 1989
  • Mårdh P-A, Paavonen J. Chlamydiainfection hos kvinnan. Allvarliga sequelae kräver diagnostisk skärpa. Läkartidningen 86: 1673–1677, 1989. (Swedish).
  • Mårdh P-A. The chlamydial epidemic with especial emphasis on European perspectives. 1st meeting of the Eur Soc for Chlamydial Research Stockholm: Almqvist & Wiksell International, 3–5, 1988
  • Bergman S, Sikström B, Mårdh P-A. Urine samples in screening of males for Chlamydia trachomatis. 8th Int Soc for Sex Trans Dis Res, Copenhagen, Denmark, September 1989, Abstract 125, 1989
  • Mårdh P-A, Stenberg K, Linder B. Chlamydiakonjunktivit—effektivare smittspårning med lagens hjälp? Läkartidningen 85: 4301–4302, 1988. (Swedish).
  • Harrison HR, Taussig LM, Fulginetti VA. Chlamydia trachomatis and chronic respiratory disease in childhood. Ped Infect Dis 1: 29–33, 1982
  • Mårdh P-A, Wølner-Hansen P. Periappendicitis and chlamydial salpingitis. Surg Gynecol Obstet 160: 304–306, 1985
  • Wølner-Hansen P, Weström L, Mårdh P-A. Perihepatitis and chlamydial salpingitis. Lancet i: 901–904, 1980
  • Muller-Schoop JW, Wang SP, Munzinger J, Schläpfer HU, Knoblauch M, Amman RW. Chlamydia trachomatis as possible cause of peritonitis and perihepatitis in young women. Br Med J 1: 1022–1024, 1978
  • Brihmer C. Studies on salpingitis. Diagnosis, etiology and therapeutical basis. Dissertation, Karolinska Institute, Stockholm, 1988
  • Grayston JT, Kuo CC, Wang SP, Cooney MK, Altman J, Marrie TJ, Marshall JG, Mordhorst CH. Clinical findings in TWAR respiratory tract infections. In: Oriel J, Ridgway G, Schachter J, Taylor-Robinson D, Ward M, eds. Chlamydial infections. Cambridge: Cambridge University Press, 337–340, 1986
  • Mårdh P-A, Paavonen J, Puolakkainen M. Chlamydia. New York: Plenum Press, 103, 1989
  • Mårdh P-A, Paavonen J, Puolakkainen M. Chlamydia. New York: Plenum Press, 104–105, 1989
  • Mårdh P-A, Paavonen J, Puolakkainen M. Chlamydia. New York: Plenum Press, 107–114, 1989
  • Møller BR, Cramers M, From E. Pivampicillin in treating genital infection with Chlamydia trachomatis. Genitourin Med 61: 264–265, 1985
  • Sandström I. Etiology and diagnosis of neonatal conjunctivitis. Dissertation, Karolinska Institute, Stockholm, 1987
  • Bowie WR. Treatment of chlamydial infections. In: Mårdh P-A, Holmes KK, Oriel JD, Piot P, Schachter J, eds. Chlamydial infections. Amsterdam: Elsevier Biomedical Press, 231–244, 1982
  • Oriel JD, Ridgway GL, Tchamonroff S. Comparison of erythromycin stearate and oxytetracycline in the treatment of nongonococcal urethritis. Scott Med J 22: 375–378, 1977
  • Hubrecht JM, Vauhoof R. Treatment of NGU patients; “Comparison of the results in chlamydia-positive and chlamydia-negative patients. In: Mårdh P-A, Holmes KK, Oriel JD, Piot P, Schachter J, eds. Chlamydial infections. Amsterdam: Elsevier Biomecial Press, 245–248, 1982
  • Csango PA, Sundersen T, Ånestad G. Double-blind comparison of erythromycin and doxycycline therapy for nongonococcal urethritis. In: Mårdh P-A, Holmes KK, Oriel JD, Piot P, Schachter J, eds. Chlamydial infections. Amsterdam: Elsevier Biomedical Press, 257–261, 1982
  • The National Collaboration NGU Treatment Group. In: Mårdh P-A, Holmes KK, Oriel JD, Piot P, Schachter J, eds. Chlamydial infections. Amsterdam: Elsevier Biomedical Press, 253–256, 1982
  • Fransen L, Avonts D, Piot P. Treatment of genital chlamydial infections with ofloxacin. Infection 14, Suppl 4: 318–320, 1986
  • Judson FN, Beals BS, Fack KJ. Clinical experience with ofloxacin in sexually transmitted disease. Infection 14, Suppl 4: 309–310, 1986
  • Nayagam AT, Ridgway GL, Oriel JD. Efficacy of ofloxacin in the treatment of non-gonococcal urethritis in men and genital infections caused by Chlamydia trachomatis in men and women. J Antimicrob Chemother 22. Suppl C: 155–158, 1988
  • Richmond SJ, Bhattacharyya MN, Maiti H, Chowdhury FH, Stirland RM, Tooth JA. The efficacy of ofloxacin against infection caused by Neisseria gonorrhoeae and Chlamydia trachomatis. J Antimicrob Chemother 22, Suppl C: 149–153, 1988
  • Ibsen HW, Møller BR, Halkier-Sørensen L, From E. Treatment of nongonococcal urethritis: Comparison of ofloxacin and erythromycin. Sex Transm Dis 16: 32–35, 1989

References

  • Schachter J. Clamydial infections. N Engl J Med 298: 428–435, 1978
  • McCormack WM. Chlamydial infections in men. In: Oriel D, Ridgway G, Schachter J, Taylor-Robinson D, Ward M, eds. Chlamydial infections. Cambridge: Cambridge University Press, 251–254, 1986
  • Oriel JD. Role of genital mycoplasms in nongonococcal urethritis and prostatitis. In: Mårdh P-A, Møller BR, McCormack WM, eds. Mycoplasma hominis—a human pathogen. New York: Lippincott, 251–254, 1983
  • Shepard MC; Lunceford CD. Differential agar medium (A7) for identification of Ureaplasma urealyticum (human T strain mycoplasmas) in primary cultures of clinical material. J Clin Microbiol 3: 613–625, 1976
  • Shepard MC, Lunceford CD. Urease color test medium u-9 for the detection and identification of “T” mycoplasmas in clinical material. Appl Microbiol 20: 539–543, 1970
  • Tully JG, Whitcomb RF, Clark HF, Williamson DL. Pathogenic mycoplasmas: Cultivation and vertebrate pathogenicity of a new spiroplasma. Science 195: 892–894, 1977
  • Ibsen HHW, Møller BR, Halkier-Sørensen L, From E. Treatment of nongonococcal urethritis: Comparison of ofloxacin and erythromycin. Sex Transm Dis 16: 32–35, 1989
  • Ripa KT, Mårdh P-A, Thelin I. Chlamydia trachomatis urethritis in men attending a venereal disease clinic: A culture and therapeutic study. Acta Derm Venereol 57: 175–179, 1978
  • Mårdh P. A.. Ascending chlamydial infection in the female genital tract. In: Oriel D, Ridgway G, Taylor-Robinson D, Ward M, eds. Chlamydial infections. Cambridge: University Press, 173–184, 1986
  • Møller BR, Mårdh P-A, Nussler E. Infection with Chlamydia trachomatis, Mycoplasma hominis and Neisseria gonorrhoeae in patients with acute pelvic inflammatory disease. Sex Transm Dis 8: 198–203, 1981
  • Eschenbach DA, Buchanan TM, Pollack HM, Forsyth PS, Wentworth BB, McCormack WM, Holmes K. Polymicrobial etiology of acute pelvic inflammatory disease. N Engl J Med 293: 166–171, 1975
  • Mårdh P-A, Weström L. Antibodies to Mycoplasma hominis in patients with genital infections and in healthy controls. Br J Vener Dis 46: 390–397, 1970
  • Piot P. Distribution of 8 serotypes of Ureaplasma urealyticum in case of nongonococcal urethritis and in healthy persons. Br J Vener Dis 52: 266–268, 1976
  • Bowie WR, Pollack HM, Forsyth PS, Floyd JF, Alexander ER, Wang S-P, Holmes KK. Bacteriology of the urethra in normal men and men with nongonococcal urethritis. J Clin Microbiol 6: 482–488, 1977
  • Bowie WR, Wang S-P, Alexander ER, Holmes KK. Etiology of nongonococcal urethritis. In: Hobson D, Holmes KK, eds. Non-gonococcal urethritis and related infections. Washington D.C.: American Society for Microbiology, 19–29, 1977
  • Prentice MJ, Taylor-Robinson D, Csonka GW. Nonspecific urethritis. A placebo-controlled trial of minocycline in conjunction with laboratory investigation. Br J Vener Dis 52: 269–275, 1976
  • Perea EJ, Aznar J, Herrera A, Mazuecos J, Rodriquez-Pichardo A. Clinical efficacy of new quinolones for therapy of nongonococcal urethritis. Sex Transm Dis 16: 7–10, 1989
  • Aznar J, Caballero MC, Lozano MC, de Miguel C, Palomeres JC, Perea EJ. Activities of new quinolone derivates against genital pathogens. Antimicrob Agents Chemother 27: 76–78, 1985

References

  • Mraovic M, Canic-Radojlovic M. The activity of ofloxacin against methicillin-resistant Staphylococcus aureus. Infection 14, Suppl 4: 231–232, 1986
  • Naber KG, Adam D, Kees F. In vitro activity and concentrations in serum urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. Drugs 34, Suppl 1: 44–50, 1987
  • Chan PY, Leung YK, Ng WWS. Comparative in vitro antibacterial activity of ofloxacin and ciprofloxacin against some selected Gram-positive and Gram-negative isolates. Infection 14, Suppl 4: 237–239, 1986
  • Hooper DC, Wolfson JS. The fluoroquinolones: Pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother 28: 716–721, 1985
  • Shimada H, Ebine Y, Kurosawa Y, Aranchi T. Mutagenicity studies of DL-8280, a new antibacterial drug. Chemotherapy 32, Suppl 1: 1170, 1984
  • Mitelman F, Kolnig A-M, Strømbeck B, Norrby R, Kromann-Andersen B, Sommer P, Wadstein J. No cytogenetic effects of quinolone treatment in humans. Antimicrob Agents Chemother 32: 936–937, 1988
  • Verho M, Dagrosa EE, Malerczyk V. Klinische Pharmakologie von Ofloxacin; ein neues Chemothera-peutikum als der Reihe der Gyrasehemmer. Infection 14, Suppl 1: 47–53, 1986
  • Lockley MR, Wise R, Dent J. The pharmacokinetics and tissue penetration of ofloxacin. Antimicrob Agents Chemother 14: 647–652, 1984
  • Hoeffler D, Koeppe P. Pharmacokinetics of ofloxacin in healthy subjects and patients with impaired renal function. Drugs 34, Suppl 1: 51–55, 1987
  • Dörfler A, Schulz W, Burkhardt F, Zichner M. Pharmacokinetics of ofloxacin in patients on hemodialysis treatment. Drugs 34, Suppl 1: 62–70, 1987
  • Vogt P, Schorn T, Frei U. Ofloxacin in the treatment of urinary tract infection in renal transplant recipients. Infection 16: 175–178, 1988
  • Wijands WJA, Vree TB, van Herwaarden CLA. The influence of quinolone derivates on theophylline concentration. Br J Clin Pharmacol 22: 677–683, 1986
  • Blomer R, Bruch K, Zohlten RN. A summary of clinical phase II and phase III study results on ofloxacin (HOE 280) in Europe. Infection 14, Suppl 1: 102–107, 1986
  • Kishi H, Nito H, Saito I, Nishimura Y, Niijima T . Comparative studies of DL-8280 and pipemidic acid in complicated urinary tract infections by double-blind method. Acta Urologica Japonica 30: 1307–1355, 1984
  • Delia S, De Simone CD, Yullo V, Sorice F. Ofloxacin: Clinical evaluation in urinary and respiratory infections. Infection 14, Suppl 4: 297–299, 1986
  • Grassi GG. A multicenter study on clinical efficacy of ofloxacin in respiratory and urinary tract infections. Infection 14, Suppl 4: 300–302, 1986
  • Cox CE, Callery SV, Tack KJ. Clinical experience with ofloxacin in urinary tract infection. Infection 14, Suppl 4: 303–304, 1986
  • Wittenberger R. Ofloxacin versus pipemidic acid and co-trimoxazole. Infection 14, Suppl 1: 93–96, 1986
  • Hoeffler D. Investigations on single-dosage treatment of urinary tract with ofloxacin. Therapiewoche 37: 2032–2034, 1987
  • Rugendorff EW. Open randomised comparison of ofloxacin and norfloxacin in the treatment of complicated urinary tract infections. Drugs 34, Suppl 1: 91–94, 1987
  • Ludwig G, Pauthner H. Clinical experience with ofloxacin in upper and lower urinary tract infections, a comparison with co-trimoxazole and nitrofurantoin. Drugs 34, Suppl 1: 95–99, 1987
  • Block JM, Walstad RA, Bjertnaes A, Hafstad P-E, Holte M, Ottemo I, Svarva PL, Rolstad T, Peterson L-E. Ofloxacin versus trimethoprim-sulphamethoxazole in acute cystitis. Drugs 34, Suppl 1: 100–106, 1987
  • Zin C, Vignera D. Treatment of the urinary tract infection: A comparative study of ofloxacin versus cotrimoxazole. Proceedings from the International Congress for Infectious Diseases, Rio de Janeiro, 1988
  • Naber KG, Sigl G. Fleroxacin versus ofloxacin in patients with complicated urinary tract infections: A controlled clinical study. Proceedings from the International Congress for Infectious Diseases, Rio de Janeiro, 1988
  • Kromann-Andersen B, Sommer P, Pers C, Larsen V, Rasmussen F. Ofloxacin compared with ciprofloxacin in the treatment of complicated lower urinary tract infections. Antimicrob Chemother 22, Suppl C: 143–147, 1988
  • Freiman JA, Calmers TC, Schmidt H, Kuebler RR. The importance of beta, type II error and sample size in the design and interpretation of the randomized control trial. N Engl J Med 299: 690–694, 1978
  • Jungst G, Mohr R. Side effects of ofloxacin in clinical trials and in postmarketing surveillance. Drugs 34, Suppl 1: 144–149, 1987
  • Huminer D, Cohen JD, Majadla R, Dux S. Hypersensitivity vasculitis due to ofloxacin. Br Med J 299: 303, 1989
  • Pace LJ, Gatt P. Fatal vasculitis associated with ofloxacin. Br Med J 299: 658, 1989

References

  • Fletcher C, Peto R, Tinker C, Speizer FE. The natural history of chronic bronchitis and emphysema. Oxford: Oxford University Press, 1976
  • Schmidt GA, Hall JB. Acute on chronic respiratory failure. Assessment and management of patients with COPD in the emergent setting. JAMA 261: 3444–3453, 1989
  • Bonde J, Dahl R, Edelstein R, Kok-Jensen A, Lazer L, Punakivi L, Seppala A, Soes-Petersen U, Viskum K. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. Eur J Respir Dis 69: 235–241, 1986
  • Boman G, Bäcker U, Larsson S, Melander B, Wåhlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: Report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 64: 405–415, 1983
  • Editorial. Antibiotics for exacerbations of chronic bronchitis. Lancet ii: 23–24, 1987
  • Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106: 196–204, 1987
  • Chodosh S. Acute bronchial exacerbations in bronchitis and asthma. Am J Med 82, Suppl 4 A: 154–163, 1987
  • Wollschlager CM, Raoof S, Khan FA, Guarneri JJ, LaBombardi V, Afzal Q. Controlled, comparative study of ciprofloxacin versus ampicillin in treatment on bacterial respiratory tract infections. Am J Med 82, Suppl 4A: 164–168, 1987
  • Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy on acute exacerbations of chronic bronchitis. A controlled study using tetracycline. Ann Intern Med 97: 18–21, 1982
  • Manresa F, Blavia R, Martin R, Linares J, Rodriguez B, Verdaguer R. Antibiotics for exacerbations of chronic bronchitis. Lancet ii: 394–395, 1987
  • Lippo K, Pelliniemi T-T, Lehto H. Trimethoprim profylaxis of acute exacerbations in chronic obstructive pulmonary diseases. Acta Med Scand 221: 455–459, 1987
  • Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Guellette VL. How often is medication taken as prescribed? Novel Assessment Technique 261: 3273–3277, 1989
  • Bartlett JG. Diagnostic accuracy of transtracheal aspiration: Bacteriologic studies. Am Rev Respir Dis 115: 777–782, 1977
  • Thys J-P. Quinolones in the treatment of bronchopulmonary infections. Rev Infect Dis 10, Suppl 1: 212–217, 1988

References

  • Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106: 196–204, 1987
  • Devogelaere R, Males P. Ofloxacin in lower respiratory tract infections—a comparison with amoxicillin. Infection 14, Suppl 4: 283–289, 1986
  • Lam WK, Chau PY, So SY, Leung YK, Chan JCK, Sham MK. A double-blind randomized study comparing ofloxacin and amoxicillin in treating infective episodes in bronchiectasis. Infection 14, Suppl 4: 290–292, 1986
  • Chantot JF, Bryskier A. Antibacterial activity of ofloxacin and other 4-quinolone derivates: In-vitro and in-vivo comparison. J Antimicrob Chemother 16: 475–484, 1985
  • Bassey CM, Baltch AL, Smith RP. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin, and ofloxacin against 177 bacterial isolates. J Antimicrob Chemother 17: 623–628, 1986
  • Kobayashi H. Clinical evaluation of ofloxacin in lower respiratory tract infections. Infection 14, Suppl 4: 279–281, 1986
  • Mitsuhashi S. International experiences with ofloxacin, a new quinolone. Infection 14, Suppl 4: 223–226, 1986
  • Sato K, Inoue Y, Fujii T, Aoyama H, Mitsuhashi S. Antibacterial activity of ofloxacin and its mode of action. Infection 14, Suppl 4: 226–231, 1986
  • Kamuda T, Neu HC. In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents. J Antimicrob Chemother 16: 563–574, 1985
  • Blommer R, Bruch K, Drauss H, Wacheck W. Safety of ofloxacin—adverse drug reactions reported during phase II studies in Europe and Japan. Infection 14, Suppl 4: 332–334, 1986

References

  • Young LS. Treatment of infections caused by gram-negative bacilli: A perspective of past, present and future. Rev Infect Dis 7, Suppl 4: 572–578, 1985
  • Neu HC. Antimicrobial activity, bacterial resistance and antimicrobial pharmacology. Am J Med 78, Suppl 6 B: 17–22, 1985
  • Bauernfeind A, Petermuller C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol 2: 111–115, 1983
  • Wolfson JS, Hooper DC. The fluoroquinolones: Structures, mechanisms of action and resistance and spectra of activity in vitro. Antimicrob Agents Chemother 28: 581–586, 1985
  • Grüneberg RN, Felmingham D, O'Hare MD, Robbins MJ, Perry U, Wall RA. Ridgway GL. The comparative in-vitro activity of ofloxacin. J Antimicrob Chemother 22, Suppl C: 9–20-1988
  • Höffken G, Lode H, Prinzing C, Borner U, Koeppe P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 27: 375–379, 1985
  • Lode H, Höffken G, Olschewski P, Sievers B, Kirch A, Borner K. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother 31: 1338–1342, 1987
  • Lode H. Pharmacokinetics and clinical results of parenterally administered new quinolones in humans. Rev Infect Dis 11, Suppl 5: 996–1004, 1989
  • Hanslo D, King A, Shannon K, Warren C, Phillips I. N-formimidoyl thienamycin (MK0787): In vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other betalactam antibiotics. J Antimicrob Chemother 7: 607–617, 1981
  • Neu HC, Labthavikul P. Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its β-lactamase stability. Antimicrob Agents Chemother 21: 180–187, 1982
  • Kropp H, Sundelof G, Hajdu R, Kahan FM. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase I. Antimicrob Agents Chemother 22: 62–70, 1982
  • Fuchs PC, Barr AL, Thoonsberry C, Jones RN. In vitro activity of ticarcillin plus clavulanic acid against 632 clincal isolates. Antimicrob Agents Chemother 25: 392–394, 1984
  • Reading E, Cole M. Clavulanic acid: A beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother 11: 852–857, 1977
  • Bertram MA, Druchner DA, Young LS. In vitro activity of HR 810, a new cephalosporin. Antimicrob Agents Chemother 26: 277–279, 1984
  • Kobayashi S, Arai S, Hayashi S, Fugimoto K. β-Lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum. Antimicrob Agents Chemother 30: 713–718, 1986
  • Lode H, Wiley R, Wagner J, Borner K. Prospective randomized controlled study of ciprofloxacin versus imipenem/cilastatin in severe clinical infections. Antimicrob Agents Chemother 31: 1491–1496, 1987
  • Bartlett JG, Drewer NS, Ryan KJ. Cumitech 7, Laboratory diagnosis of lower respiratory tract infections. Coordinating ed, JA Washington II. Washington DC: American Society for Microbiology, 1978
  • Maesen FPV, Davies BJ, Geraedts WH, Baur C. The use of quinolones in respiratory tract infections. Drugs 34, Suppl 1: 74–79, 1987
  • Grassi C, Gialdrone Grassi G, Mangiarotti P. Clinical efficacy of ofloxacin in lower respiratory tract infections. Drugs 34, Suppl 1: 80–82, 1987
  • Egede F, Kristensen J. A clinical comparative study of ofloxacin and pivampicillin in acute exacerbation of chronic bronchitis. J Antimicrob Chemother 22, Suppl C: 139–142, 1988
  • Petersen SS. Clinical efficacy of ciprofloxacin in lower respiratory tract infections. Scand J Infect Dis 60: 89–97, 1989
  • Thys JP, Jacobs F, Motte S. Quinolones in the treatment of lower respiratory tract infections. Rev Infect Dis 11, Suppl 5: 1212–1219, 1989
  • Scandinavian Study Group. Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Lancet i: 868–871, 1984
  • Wang C, Pappas F, Cook T. Imipenem/cilastatin—a multicentre international study of its clinical efficacy, safety and potential as empirical therapy. J Antimicrob Chemother 18, Suppl E: 185–192, 1986
  • Roselle GA, Bode R, Hamilton B, Bibler M, Sullivan R, Douce R, Staneck JL, Bullock WE. Clinical trial of the efficacy and safety of ticarcillin and clavulanic acid. Antimicrob Agents Chemother 27: 291–296, 1989

References

  • Davies BI, Maesen FPV. Quinolones in chest infections. J Antimicrob Chemother 18: 296–299, 1986
  • Wijnands WJA, Vree TB, van Heerwarden CLA. The influence of quinolone derivatives on theophyllin clearance. Br J Clin Pharmacol 22: 677–683, 1986
  • Gialdroni-Grassi G. A multi-center study on clinical efficacy of ofloxacin in respiratory and urinary tract infections. Infection 14, Suppl 4: 300–302, 1986
  • Devogelaere R, Maes P. Ofloxacin in lower respiratory infections—a comparison with amoxycillin. Infection 14, Suppl 4: 283–289, 1986
  • Egede F, Kristensen I. A clinical comparative study of ofloxacin and pivampicillin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 22, Suppl C: 139–142, 1988
  • Kobayashi H. Clinical evaluation of ofloxacin in lower respiratory tract infections. Infection 14, Suppl 4: 279–282, 1986
  • Kumada T, Neu HC. In vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antibacterial agents. J Antimicrob Chemother 16: 563–574, 1985
  • Gruneberg RN, Felmingham D, O'Hare MD, Robbins MJ, Perry K, Wall RA, Ridgway GL. The comparative in vitro activity of ofloxacin. J Antimicrob Chemother 22, Suppl C: 9–19, 1988
  • Wise R, Andrews JM, Danks G. In vitro activity of enoxacin (CI-919), a new quinolone derivative, compared with that of other antimicorbial agents. J Antimicrob Chemother 13: 237–244, 1984
  • Yamaguchi K, Nakazato H, Koga H, Watanabe K, Tomita H. Laboratory studies and clinical evaluations of DL-8280 to the patients with respiratory infections. Chemotherapy (Tokyo) 32, Suppl 1: 487–508, 1984
  • Davies BI, Maesen FPV, Geraedts WH, Baur C. Penetration of ofloxacin from blood to sputum. Drugs 34, Suppl 1: 26–32, 1987
  • Couraud L, Fourtillan JB, Saux MC, Bryskier A, Vincent du Laurier M. Diffusion of ofloxacin into human lung tissue. Drugs 34, Suppl 2: 37–38, 1987
  • Wijnands WJA, Vree TB, Baars AM, Hafkenscheid JCM, Kohler BEM van Heerwarden CLA. The penetration of ofloxacin into lung tissue. J Antimicrob Chemother 22, Suppl C: 85–89, 1988
  • Davey PG, Winter J, Precious E, Moreland T. Ofloxatin concentrations in bronchial mucosa during oral treatment for acute exacerbations of chronic bronchitis. Proceedings of 29th ICAAC, Houston, USA, September 1989
  • Fourtillan JB, Granier J, Saint-Salvi B, Salmon J, Surjus A, Tremblay D, Vincent du Laurier M, Beck S. Pharmacokinetics of ofloxacin and theophylline alone and in combination. Infection 14, Suppl 1: 67–69, 1986
  • Wijnands WJA, Vree TB, Baars AM, van Heerwarden CLA. Steady-state kinetics of the quinolone derivatives, ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline. Drugs 34, Suppl 1: 159–169, 1987
  • Davies BI, Maesen FPV. Respiratory infections: Clinical experiences with the new quinolones. Pharm Weekbl (Sci) 9, Suppl: 53–57, 1987

References

  • Gruneberg RN, Felmingham D, O'Hare MD, Robbins MJ, Perry K, Wall RA. Ridgway GL. The comparative in vitro activity of ofloxacin. J Antimicrob Chemother 22, Suppl C: 9–20, 1988
  • Wise R, Lockley MR. The pharmacokinetics of ofloxacin and a reveiw of its tissue penetration. J Antimicrob Chemother 22, Suppl C: 59–64, 1988
  • Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 5: 492–493, 1968
  • Thomas V, Shelokov A, Forland N. Antibody coated bacteria in the urine and site of urinary tract infection. N Engl J Med 290: 588–590, 1974
  • Shah PM, Frech K. Clinical experience with quinolones-overview. Quinolones Bulletin, November 1985
  • Kromann-Andersen B, Sommer P, Pers C, Larsen V, Rasmussen F. Ofloxacin compared with ciprofloxacin in the treatment of complicated lower urinary tract infections. J Antimicrob Chemother 22, Suppl C: 143–147, 1988
  • Egede F, Kristensen I. A clinical comparative study of ofloxacin and pivampicillin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 22, Suppl C: 139–142, 1988
  • Blomer R, Bruch K, Zahlten RN. Zusammengefasste Ergebnisse der klinischen Phase II und III Studien mit Ofloxacin (HOE 280) in Europa. Infection 14, Suppl 1: 102–107, 1986
  • Bruch K. Klinische Ergebnisse mit Ofloxacin. Fortschr Antimikrob Antineopl Chemother 3–4: S741–748, 1984
  • Daikos GK, Kosmidis J, Stathakis C, Giamarellou H, Douzinas E . Ceftazidime: Therapeutic results in various infections and kinetic studies. J Antimicrob Chemother 8, Suppl B: 331–337, 1981
  • Giamarellou H, Galanakis N, Douzinas E, Petrikkos G, El Messidi M, Papoulias G, Daikos GK. Evaluation of aztreonam in difficult-to-treat infections with prolonged post-treatment follow-up. Antimicrob Agents Chemother 26: 245–249, 1984
  • Giamarellou H. Galanakis N, Christidis K, Dokianakis G. Malignant external otitis and the newer quinolones. Rev Infect Dis 11, Suppl 5: 1109–1110, 1989
  • Ketterl R, Beckurts T, Stubinger B, Claudi B. Use of ofloxacin in open fractures and in the treatment of post-traumatic osteomyelitis. J Antimicrob Chemother 22, Suppl C: 159–166, 1988

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.